Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 2;2016(1):269-276.
doi: 10.1182/asheducation-2016.1.269.

Prognostic factors in follicular lymphoma: new tools to personalize risk

Carla Casulo  1
Affiliations
Review

Prognostic factors in follicular lymphoma: new tools to personalize risk

Carla Casulo. Hematology Am Soc Hematol Educ Program. .

Abstract

Follicular lymphoma (FL) is the most common indolent lymphoma, and it has a long median overall survival (OS). However, the recent discovery of clinical and biological prognostic biomarkers in FL is shedding light on FL heterogeneity and the need for a precise and risk-stratified individual approach at diagnosis and relapse. Many FL patients who are asymptomatic with indolent disease can be vulnerable to the toxicity, emotional distress, and financial burden of overtreatment. Yet a subset of FL patients develop chemoresistance to standard chemoimmunotherapy, experience transformation to aggressive lymphoma and rapid progression, and represent the population most in need of novel therapies and curative approaches. Novel biomarkers that incorporate both clinical and genetic determinants of poor risk are being developed with the hope of identifying high-risk patients at diagnosis in order to offer biologically rational targeted therapies.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author is a member of the Celgene Scientific Steering Committee and has received research funding from Celgene.

Figures

Figure 1.
Figure 1.
Poor survival in FL patients with early relapse after R-CHOP therapy.
See this image and copyright information in PMC

References

    1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276. - PMC - PubMed
    1. Sant M, Allemani C, Tereanu C, et al. ; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724-3734. - PubMed
    1. Casulo C, Day B, Dawson KL, et al. . Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study. Ann Oncol. 2015;26(11):2311-2317. - PMC - PubMed
    1. Friedberg JW, Taylor MD, Cerhan JR, et al. . Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202-1208. - PMC - PubMed
    1. Conconi A, Lobetti-Bodoni C, Montoto S, et al. . Life expectancy of young adults with follicular lymphoma. Ann Oncol. 2015;26(11):2317-2322. - PubMed

Substances

LinkOut - more resources